PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
150.15%
Some net income increase while VET is negative at -105.21%. John Neff would see a short-term edge over the struggling competitor.
5.84%
Some D&A expansion while VET is negative at -6.49%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
11.63%
Some yoy growth while VET is negative at -105.53%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
98.40%
Slight usage while VET is negative at -130.97%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
98.40%
Some yoy usage while VET is negative at -130.97%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
160.04%
Lower 'other non-cash' growth vs. VET's 1320.75%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
107.95%
Some CFO growth while VET is negative at -73.77%. John Neff would note a short-term liquidity lead over the competitor.
-10.91%
Negative yoy CapEx while VET is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
-100.00%
Negative yoy acquisition while VET stands at 0.00%. Joel Greenblatt sees potential short-term cash advantage unless competitor’s deals yield big synergy.
-100.00%
Negative yoy purchasing while VET stands at 0.00%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
-100.00%
We reduce yoy sales while VET is 0.00%. Joel Greenblatt sees competitor possibly capitalizing on market peaks or forced to raise cash while we hold tight.
208.20%
Growth well above VET's 52.20%. Michael Burry would suspect heavier intangible or side spending overshadowing competitor’s approach, risking short-term FCF.
94.82%
Investing outflow well above VET's 52.20%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
7.38%
We slightly raise equity while VET is negative at -84.81%. John Neff sees competitor possibly preserving share count or buying back shares.
No Data
No Data available this quarter, please select a different quarter.